Therapeutic success of a prospective cardioversion protocol for persistent atrial fibrillation;Rendimiento terapéutico de un protocolo prospectivo de cardioversión en la fibrilación auricular persistente

Revista Espanola de Cardiologia

Volumn 59, Issue 10, 2006, Pages 1038-1046

  Martínez Brotóns, Ángel M ^a,b   Ruiz Granell, Ricardo ^a   Morell, Salvador ^a   Plancha, Eva ^a   Ferrero, Ángel ^a   Roselló, Araceli ^a   Llácer, Ángel ^a   García Civera, Roberto ^a  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b NONE   (Spain)

Author keywords

Antiarrhythmics; Atrial fibrillation; Cardioversion; Recurrence

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT;

ADULT; AGED; ARTICLE; CARDIOVERSION; CLINICAL PROTOCOL; DISEASE DURATION; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PROSPECTIVE STUDY; RECURRENCE RISK; RISK FACTOR; SCORING SYSTEM; SINUS RHYTHM; UNSPECIFIED SIDE EFFECT;

EID: 35949000356     PISSN: 03008932     EISSN: None     Source Type: Journal    
DOI: 10.1157/13093981     Document Type: Article

References (34)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham Study. Stroke. 1991;22:983-8.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation. 1998;98:946-52.
3. Chung SS, Blackshear JL, Gersh BJ. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001;37:371-8.
4. García-Acuña JM, González-Juanatey JR, Alegría E, González I, Listerri JL. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio Cardiotens 1999. Rev Esp Cardiol. 2002;55:943-52.
5. Moro C, Hernández A. Cardioversión eléctrica para la fibrilación auricular. ¿ZExisten aún indicaciones tras el estudio AFFIRM? Rev Esp Cardiol. 2003;56:751-3.
6. Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825-33.
7. Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834-40.
8. Fuster V, Ryden LE, Asinger RW, Cannon DS, Crijns HJ, Frye RL, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation. Eur Heart J. 2001;22:1852-923.
9. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (DIAMOND) substudy. Circulation. 2001;104:292-6.
10. Corley SD, Epstein AE, DiMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Study. Circulation. 2004;109: 1509-13.
11. Van Gelder IC, Crijns HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med. 1996;156:2585-92.
12. Gosselink AT, Crijns HJ, Van Gelder IC, Hillige H, Wiesfeld AC, Lie KI. Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992;267:3289-93.
13. Lundstrom T, Ryden L. Chronic atrial fibrillation. Long-term results of direct current conversion. Acta Med Scand. 1988;223:53-9.
14. Berry C, Stewart S, Payne EM, McArthur JD, McMurray JJ. Electrical cardioversion for atrial fibrillation: outcomes in «real-life» clinical practice. Int J Cardiol. 2001;81:29-35.
15. AFFIRM First Antiarrhythmic Drug Substudy Investigators. Maintenance of sinus rhythm in patients with atrial fibrillation: an AFFIRM substudy of the first antiarrhythmic drug. J Am Coll Cardiol. 2003;42:20-9.
16. Roy D, Talajic M, Dorian P, Connolly S, Eisenberg MJ, Green M, et al. Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med. 2000;342:913-20.
17. Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med. 2005;352:1861-72.
18. Connolly SJ. Meta-analysis of antiarrhythmic drug trials. Am J Cardiol. 1999;84:R90-3.
19. Kirchhof P, Borggrefe M, Breithardt G. Effect of electrode position on the outcome of cardioversion. Card Electrophysiol Rev. 2003;7:292-6.
20. Ewy GA. The optimal technique for electrical cardioversion of atrial fibrillation. Clin Cardiol. 1994;17:79-84.
21. Capucci A, Villani GQ, Aschieri D, Rosi A, Piepoli MF. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation. Eur Heart J. 2000;21:66-73.
22. Oral H, Brinkman K, Pelosi F, Flemming M, Tse HF, Kim MH, et al. Effect of electrode polarity on the energy required for transthoracic atrial defibrillation. Am J Cardiol. 1999;84:228-30.
23. Cohen TJ, Ibrahim B, Denier D, Haji A, Quan W. Active compression cardioversion for refractory atrial fibrillation. Am J Cardiol. 1997;80:354-5.
24. BiCard Investigators. Biphasic versus monophasic shock wave-form for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. J Am Coll Cardiol. 2002;39:1956-63.
25. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol. 1991;68:41-6.
26. Frick M, Frykman V, Jensen-Urstad M, Ostergren J, Rosenqvist M. Factors predicting success rate and recurrence of atrial fibrillation after first electrical cardioversion in patients with persistent atrial fibrillation. Clin Cardiol. 2001;24:238-44.
27. Lehto M, Kala R. Persistent atrial fibrillation: a population based study of patients with their first cardioversion. Int J Cardiol. 2003;92:145-50.
28. Ortiz JA, Del Carmen M, Ochoa C, De la Fuente L, Moreno JC, Del Campo F, et al. Factores predictores independientes del éxito agudo y al año de la cardioversión eléctrica en pacientes con fibrilación auricular crónica. Rev Esp Cardiol. 2001; 54:958-64.
29. Bertaglia E, D'Este D, Zerbo F, Zoppo F, Delise P, Pascotto P. Success of serial external electrical cardioversion of persistent atrial fibrillation in maintaining sinus rhythm; a randomized study. Eur Heart J. 2002;23:1522-8.
30. AFFIRM Investigators. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J. 2006;151:390-6.
31. Arnar DO, Danielsen R. Factors predicting maintenance of sinus rhythm after direct current cardioversion of atrial fibrillation and flutter: a reanalysis with recently acquired data. Cardiology. 1996;87:181-8.
32. Madrid AH, Bueno MG, Rebollo IM, Marín I, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: a prospective and randomized study. Circulation. 2002;106:331-6.
33. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J. 2003;24:2090-8.
34. Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, et al. Prevention of Atrial Fibrillation after Cardioversion Investigators. Prevention of atrial fibrillation after cardioversion: results of the PAFAC trial. Eur Heart J. 2004;25:1385-94.